Get the Stockscreener App
110.82
0.21%
0.16
Axsome Therapeutics Inc stock is traded at $110.82, with a volume of 248.33K.
It is up +0.21% in the last 24 hours and down -1.13% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$110.66
Open:
$112
24h Volume:
248.33K
Relative Volume:
0.37
Market Cap:
$5.46B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-16.97
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+5.45%
1M Performance:
-1.13%
6M Performance:
+10.78%
1Y Performance:
+48.33%
1-Day Range:
$110.22
$113.30
1-Week Range:
$105.36
$113.30
52-Week Range:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
110.96 | 5.15B | 338.46M | -310.96M | -132.82M | -6.53 |
|
ONC
Beone Medicines Ltd Adr
|
256.46 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.62 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.64 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
496.88 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics at Jefferies: Strategic Growth and Pipeline Expansion - Investing.com
Oppenheimer Initiates Coverage of Axsome Therapeutics (LSE:0HKF) with Outperform Recommendation - Nasdaq
2 Soaring Stocks Wth More Upside Potential - AOL.com
2 Soaring Stocks Wth More Upside Potential - The Motley Fool
111 Capital Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report? - Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Oppenheimer - Defense World
Morgan Stanley Remains Bullish on Axsome (AXSM), Reiterates $190 PT - MSN
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Two Sigma Advisers LP - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4.88 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Two Sigma Advisers LP Raises Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
Ameriprise Financial Inc. Has $1.54 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Oppenheimer Initiates Coverage of Axsome Therapeutics (BMV:AXSM) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Coverage of Axsome Therapeutics (BIT:1AXSM) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Coverage of Axsome Therapeutics (AXSM) with Outperform Recommendation - Nasdaq
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman Sells 3,750 Shares of Stock - MarketBeat
Oppenheimer Initiates Axsome Therapeutics (AXSM) with Outperform Rating - GuruFocus
Axsome Therapeutics Headed for Positive Growth With Ample Pipeline , Oppenheimer Says in New Research - marketscreener.com
Oppenheimer Initiates Coverage on Axsome Therapeutics (AXSM) wit - GuruFocus
Axsome initiated with Outperform at Oppenheimer (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics (AXSM) Gains Positive Outlook with Analyst C - GuruFocus
Oppenheimer Initiates Axsome Therapeutics at Outperform With $185 Price Target - marketscreener.com
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of AXSM, ET and APPS - ACCESS Newswire
Mark L. Jacobson Sells 20,673 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
Q2 EPS Forecast for Axsome Therapeutics Boosted by Analyst - MarketBeat
Mark L. Jacobson Sells 20,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
Ameriprise Financial Inc. Sells 179,697 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
How To Trade (AXSM) - news.stocktradersdaily.com
TFG Asset Management GP Ltd Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Trimmed by Wellington Management Group LLP - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for AXSM - Defense World
Hedge Fund and Insider Trading News: Chris Rokos, Ray Dalio, Paul Marshall, Edward Charles Molson, Third Point, Soroban Capital Partners, Whale Rock Capital Management, Elliott Management, Vestis Corp (VSTS), Axsome Therapeutics Inc (AXSM), and - Insider Monkey
Axsome Therapeutics Sets Strong Institutional Presence with Three Elite Healthcare Conference Presentations - Stock Titan
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Nuveen Asset Management LLC Increases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
ProShare Advisors LLC Acquires 2,942 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares By Investing.com - Investing.com India
Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares - Investing.com Australia
Axsome Therapeutics Secures US$570 Million Financing and Equity Investment from Blackstone - Global Legal Chronicle
Axsome settles patent dispute with Hetero Labs over Sunosi generic - MSN
Axsome Unveils Breakthrough Data from 3 CNS Programs: New Results for Depression, Alzheimer's, and Sleep Disorders - Stock Titan
Axsome, Hetero Settle Patent Fight on Daytime-Sleepiness Drug - Bloomberg Law News
Axsome and Hetero settle patent fight over sleep disorder drug - Endpoints News
Axsome's solriamfetol shows mixed results amid 13 phase III wins in April - BioWorld MedTech
Axsome Therapeutics (AXSM) Resolves Patent Dispute Over Sunosi G - GuruFocus
Axsome Reaches Settlement With Hetero Labs Over Sunosi Patent Dispute; Shares Up Pre-Bell - marketscreener.com
Axsome Therapeutics Settles Sunosi Patent Litigation With Hetero Labs - marketscreener.com
Axsome settles patent lawsuit with Hetero over SUNOSI By Investing.com - Investing.com Nigeria
Axsome settles Sunosi patent dispute with Hetero (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coleman Mark | Director |
May 28 '25 |
Sale |
103.43 |
3,750 |
387,862 |
46,637 |
| Jacobson Mark L. | Chief Operating Officer |
May 27 '25 |
Option Exercise |
6.47 |
20,673 |
133,754 |
26,456 |
| Jacobson Mark L. | Chief Operating Officer |
May 28 '25 |
Option Exercise |
6.47 |
20,000 |
129,400 |
25,783 |
| Jacobson Mark L. | Chief Operating Officer |
May 27 '25 |
Sale |
104.66 |
20,673 |
2,163,636 |
5,783 |
| Jacobson Mark L. | Chief Operating Officer |
May 28 '25 |
Sale |
103.45 |
20,000 |
2,069,000 |
5,783 |
1.30%
3.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):